Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12658375rdf:typepubmed:Citationlld:pubmed
pubmed-article:12658375lifeskim:mentionsumls-concept:C0001792lld:lifeskim
pubmed-article:12658375lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:12658375lifeskim:mentionsumls-concept:C0003595lld:lifeskim
pubmed-article:12658375lifeskim:mentionsumls-concept:C0010286lld:lifeskim
pubmed-article:12658375lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:12658375lifeskim:mentionsumls-concept:C0205216lld:lifeskim
pubmed-article:12658375lifeskim:mentionsumls-concept:C1742737lld:lifeskim
pubmed-article:12658375lifeskim:mentionsumls-concept:C0439098lld:lifeskim
pubmed-article:12658375pubmed:issue3lld:pubmed
pubmed-article:12658375pubmed:dateCreated2003-3-26lld:pubmed
pubmed-article:12658375pubmed:abstractTextApolipoprotein E (ApoE) genotype has been shown to influence results in neuroimaging studies using a number of various imaging modalities. No in vivo data exists on whether or not there are ApoE-related changes observable by proton magnetic resonance spectroscopy (MRS). In this study we measured absolute peak areas of proton MR spectra obtained from the occipital cortex in 22 non-demented elderly with (n = 8) or without (n = 14) the ApoE epsilon4 allele. No statistically significant differences were found in levels of N-acetyl aspartate, myo-inositol, or choline containing compounds between the groups. Instead, compared with the non-carriers, the levels of creatine were significantly lower in the epsilon4 carriers, suggesting increased metabolic demands in the brain of the epsilon4 carriers. The levels of creatine also correlated significantly with age and performance on the Mini-Mental State Examination test in the epsilon4 carriers, but not in the non-carriers. These findings may be of significant clinical interest as potential indicator of incipient AD, and also from therapeutical point of view given the potential neuroprotective effects of creatine.lld:pubmed
pubmed-article:12658375pubmed:languageenglld:pubmed
pubmed-article:12658375pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12658375pubmed:citationSubsetIMlld:pubmed
pubmed-article:12658375pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12658375pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12658375pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12658375pubmed:statusMEDLINElld:pubmed
pubmed-article:12658375pubmed:monthMarlld:pubmed
pubmed-article:12658375pubmed:issn0300-9564lld:pubmed
pubmed-article:12658375pubmed:authorpubmed-author:KönönenMMlld:pubmed
pubmed-article:12658375pubmed:authorpubmed-author:SoininenHHlld:pubmed
pubmed-article:12658375pubmed:authorpubmed-author:HiltunenYYlld:pubmed
pubmed-article:12658375pubmed:authorpubmed-author:LachalCClld:pubmed
pubmed-article:12658375pubmed:authorpubmed-author:HallikainenMMlld:pubmed
pubmed-article:12658375pubmed:authorpubmed-author:KoivistoAAlld:pubmed
pubmed-article:12658375pubmed:authorpubmed-author:KivipeltoMMlld:pubmed
pubmed-article:12658375pubmed:issnTypePrintlld:pubmed
pubmed-article:12658375pubmed:volume110lld:pubmed
pubmed-article:12658375pubmed:ownerNLMlld:pubmed
pubmed-article:12658375pubmed:authorsCompleteYlld:pubmed
pubmed-article:12658375pubmed:pagination267-75lld:pubmed
pubmed-article:12658375pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:meshHeadingpubmed-meshheading:12658375...lld:pubmed
pubmed-article:12658375pubmed:year2003lld:pubmed
pubmed-article:12658375pubmed:articleTitleDecreased brain creatine levels in elderly apolipoprotein E epsilon 4 carriers.lld:pubmed
pubmed-article:12658375pubmed:affiliationDepartment of Neurology, Clinical Radiology, Kuopio University Hospital, Kuopio, Finland. mikko.laakso@uku.filld:pubmed
pubmed-article:12658375pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12658375pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:12658375pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:348entrezgene:pubmedpubmed-article:12658375lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:12658375lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12658375lld:pubmed